Jochen Greiner

Stuttgart, BW 70176, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer.

Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer.

Journal: Scientific reports

Published: September 10, 2025

Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.

Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.

Journal: Leukemia

Published: April 24, 2025

Atacama Large Aperture Submillimeter Telescope (AtLAST) science: Probing the transient and time-variable sky.

Atacama Large Aperture Submillimeter Telescope (AtLAST) science: Probing the transient and time-variable sky.

Journal: Open research Europe

Published: January 08, 2025

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

Journal: EBioMedicine

Published: November 15, 2024

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

Journal: Cancers

Published: June 19, 2024

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Journal: Leukemia

Published: December 20, 2023

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Journal: International journal of molecular sciences

Published: March 08, 2023

A helium-burning white dwarf binary as a supersoft X-ray source.

A helium-burning white dwarf binary as a supersoft X-ray source.

Journal: Nature

Published: September 14, 2022

Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Journal: International journal of molecular sciences

Published: January 17, 2022

Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.

Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.

Journal: British journal of haematology

Published: January 14, 2022

Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report.

Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report.

Journal: European journal of medical research

Published: October 02, 2021

Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.

Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.

Journal: International journal of molecular sciences

Published: September 13, 2021

Showing 1-12 of 54

Last Updated: 09/26/2026